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A recent study has identified the variation in the
ADAM33 gene as an important risk factor for
asthma. This is not only good news for asthma
sufferers, suggesting new directions for diagnostics
and treatment, but also provides encouragement
that unravelling the genetics of common diseases
may not be quite as hard as had been feared.
Asthma is a common, complex, autoimmune disorder
[1] which is estimated to affect about 155 million
individuals worldwide. Along with its associated clinical
phenotypes, asthma has been under vigorous genetic
investigation for many years. Like most other common
diseases, the genetics of asthma has been investigated
using both family-based and population based
approaches [2]. Up until now, the results have been
largely disappointing, highlighting the difficult task faced
by researchers trying to unravel the genetic architecture
of multifactorial diseases such as asthma, diabetes,
hypertension and the neuropsychiatric conditions.
But now Van Eerdewegh et al. [3] have identified a
gene, ADAM33, which seems to be an important risk
factor in asthma and bronchial hyperresponsiveness.
They took a sequential approach to the problem (Figure
1). Using a coarse set of highly variable genetic markers
— microsatellites — spaced approximately every 10 cM
throughout the genome, they first assessed the sharing
of marker alleles in affected sib pairs. Under the null
model of no physical linkage to disease-causing alleles,
affected siblings are expected to share half their alleles
at a marker locus. Markers linked to disease causing
alleles, however, are expected to show an excess of
allele sharing between affected sibs. 
In their affected sib analysis, Van Eerdewegh et al.
[3] used two different phenotypic criteria: asthma only
and asthma with an additional related, quantitative
phenotypic feature — bronchial hyperresponsiveness,
elevated serum immunoglobulin E or positive specific
immunoglobulin E. The analysis implicated a region
spanning approximately 25 cM of chromosome 20
(20p13). Affected sib pair analyses, like other designs
for detecting linkage, are often effective in the early
stages of mapping but usually implicate fairly large
stretches of genomic sequence within which the
causal variant(s) may reside. In this case, Van
Eerdewegh et al. [3] focused their efforts on a 5 cM
region or about 2.5 megabases of DNA spanning the
highest point of the linkage peak.
To pinpoint the risk factors within this long stretch of
genomic sequence, Eederwegh et al. [3] turned to an
association study. The basic approach used in an
association study is straightforward. To test whether a
single nucleotide polymorphism (SNP) is associated
with a disease — either directly because it itself is
causal, or indirectly because it is in linkage disequilib-
rium [4] with one or more other causative polymor-
phisms — allele frequencies can be compared in
affected (cases) and unaffected (controls) using simple
statistical tools. The prospects for fine localization are
improved because instead of depending on the recom-
bination events within a pedigree, as must be done in
a linkage study, association studies capitalize on
recombination events that have taken place over many
generations within a population.
Using the rough draft of the human genome [5] as
reference and a combination of molecular sequencing
strategies, Eederwegh et al. [3] characterised 40 genes
of which 23 were selected as potential candidate
genes to focus the selection of SNP identification.
These 23 genes were deemed as candidates based on
potential function, relevant tissue expression (lung),
and physical location with respect to the peak loga-
rithm of odds (LOD) score — the quantitative measure
of the probability that the observed linkage is signifi-
cant. Altogether 135 single nucleotide polymorphisms
were identified, genotyped and used in tests of asso-
ciation. Twenty-four single nucleotide polymorphisms
showed significant association with asthma and
bronchial hyperresponsiveness.
When a variant has a frequency difference between
cases and controls, there are two possible explana-
tions. First, it may be a real effect. That is, the variant is
either a risk factor or in linkage disequilibrium with a
risk factor. The second possibility, however, is that the
frequency difference results from cryptic population
stratification. If the cases and controls are drawn from
subpopulations that have differences in disease inci-
dence, then any marker showing an allele frequency
difference between the subpopulations will show an
allele frequency difference between the cases and the
controls. One solution to this problem is to use family-
based controls, as for example in the transmission dis-
equilibrium class of tests [6] which use parental
chromosomes as controls, opposed to those from ran-
domly selected healthy individuals. Eederwegh et al.
[3] show that the association observed in the case-
control comparison was also observed in a transmis-
sion disequilibrium test, ruling out spurious association
due to population stratification.
The majority of the positive associations occurred 
in the gene ADAM33. Haplotypes were then con-
structed and their frequencies compared in tests 
of association. In all cases, much greater significance
was observed for haplotypes versus individual SNPs.
ADAM33 is a member of a family of genes that encode
proteins with proteolytic activity and that are primarily
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expressed in lung fibroblasts and bronchial smooth
muscle. Thus ADAM33 now joins a very small list of
genes that have been identified as common disease
risk factors through population based gene mapping,
including calpain-10, a risk factor for type 2 diabetes
mellitus [6], and NOD2, a risk factor for Crohn’s
disease [7,8].
The difficulty researchers have encountered in
mapping genes for multifactorial diseases are not
surprising. There are many reasons to be pessimistic.
We still know extremely little about the genetics of
common diseases, and as has been extensively
discussed recently, the details of genetic causation will
determine the success of linkage disequilibrium-based
mapping efforts. Perhaps the most important questions
concern the frequency of variants influencing common
diseases. The utility of the genome-wide characteriza-
tion of linkage disequilibrium envisioned in the HapMap
project [9] will depend on the applicability of the
‘common disease–common variant’ framework which
postulates that the alleles conferring susceptibility to
common diseases are themselves common and gener-
ally found in multiple human populations [10]. If the
causal mutations have low frequencies, however, as
has been observed in some cases [8,10] and predicted
by at least some theoretical analyses ([11] for example,
but see also [12] which reaches the opposite conclu-
sion), then association approaches, as they are nor-
mally now implemented, will not be effective. 
A related, but distinguishable, question is the
extent of genetic heterogeneity [13]. It is well known
that the allelic spectrum underlying single locus dis-
orders is relatively diverse, that is, many different
alleles at a single locus cause disease. If the spectra
for common diseases turned out to be similarly
diverse, then association approaches will again be
suboptimal. Another layer of complexity is introduced
by our ignorance of patterns of linkage disequilibrium
in human populations [14]. Finally, the definition of
disease itself can introduce serious problems.
Disease state can serve as an ill-defined phenotype
for genetic analysis, as the distinction between health
and disease, which involves a multitude of underlying
pathophysiological activities, is often ignored. This
can make the predictability of the disease by its
underlying genes weak, resulting in unrealistic sample
size requirements.
The new study by Eedewegh et al. [3] however, offers
reassurance on most of these points. Firstly, through
the use of intermediate, quantitative phenotypes in con-
junction with disease end-points, the authors added
significant statistical power to their study, as such 
phenotypes potentially represent genetically and envi-
ronmentally more homogenous correlates for putative
disease causing alleles [15]. This point is exemplified 
by the more significant maximum LOD score from 
the results of the scan that included asthma plus
bronchial hyperresponsiveness, as opposed to the
asthma-only linkage scans, even though the sample
size for the asthma-only scan was nearly double that of
the other scan. This result should encourage human
geneticists to move beyond the disease-event focus of
early association studies.
Secondly, the genome region encompassing the
ADAM33 gene has many of the characteristics
required to be suitable for linkage disequilibrium-
dependent association mapping, and also conforms
nicely to the common disease–common variant
framework as a working model. For example, contrary
to the findings for NOD2 [7], in the case for Crohn’s
disease, the ADAM33 gene variants that increase
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Figure 1. Schematic diagram of the three main stages leading
to the genetic mapping of ADAM33.
In stage 1, two-generation asthma affected sib-pair families (A)
were collected and genotyped for highly variable microsatel-
lite markers (shown as vertical line above the chromosome)
spaced at 10 cM intervals throughout the genome. (B) Linkage
analysis was then used to identify a region of 2.5 megabases,
on the short arm of chromosome 20, 20p13. In stage 2, the
20p13 chromosomal region was explored using the rough
sequence of the human genome to identify potential candidate
genes that were used for single nucleotide polymorphism
(SNP) detection and association mapping. Altogether, 135
SNPs (arrows) were identified in 23 putative candidate genes
(blocks). In stage 3, linkage disequilibrium-based association
mapping is carried out using two different types of tests: the
population-based case-control (C) and family-based transmis-
sion disequilibrium test (D).
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susceptibility to asthma are all common, with fre-
quencies above 20%.
Thirdly, the sequential approach used by Eedewegh
et al. [3] (Figure 1) proves that linkage and association
approaches can be fruitfully combined without having
to resort to the currently expensive and time-consum-
ing genome-wide association mapping of complex 
diseases. And finally, this study lends further support
to the ‘candidate-gene’ approach for studying complex
traits and highlights the fact that biological insight 
into disease pathophysiology and common-sense pri-
oritisation provides us with two valuable tools with
which a considerable amount of time and cost can 
be saved [16].
Two other points deserve further discussion. First,
while the extent of useful linkage disequilibrium [17]
around ADAM33 might be higher than usual, it is
unlikely that reduced linkage disequilibrium will impose
a real constraint on linkage disequilibrium-based gene
mapping. Recent evidence suggests that, as long as
the causal variants are common, tagging SNPs can be
identified that will represent most of the variation in a
target region — such as in the linkage implicated
region studied here — or within candidate genes [18].
There would just need to be a larger or smaller set of
tagging SNPs depending on the local extent of linkage
disequilibrium. Finally, it is interesting to note that
some of the SNPs in significant association with
asthma and bronchial hyperresponsiveness are
located in non-coding regions including introns and 3′
untranslated regions. This highlights the importance of
characterising genetic variation in regulatory as well as
coding gene segments [19], and argues against an
‘exons first’ approach to association studies [20].
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